A CD40-Targeted IL-21 Fusokine Enables Rapid Generation of Human IL-10⁺Granzyme B⁺ Regulatory B Cells
Preprint
Abstract
Regulatory B cells (Bregs) have emerged as important modulators of immune homeostasis, complementing the classical roles of B cells in antibody production, antigen presentation, and provision of costimulatory signals and cytokines. Beyond promoting immunity, B cells can actively suppress inflammatory responses through specialized regulatory programs that limit effector T cell expansion and restrain pathogenic myeloid activation. These suppressive functions are mediated by mechanisms including secretion of IL-10, IL-35, and TGF-β, expression of inhibitory ligands, and release of granzyme B. However, Bregs are rare and heterogeneous in humans, typically comprising less than 1–2% of circulating B cells, and defects in their frequency or function are associated with autoimmune and inflammatory diseases. The scarcity of endogenous Bregs has driven interest in their ex vivo generation as a cellular immunotherapy. Although several strategies efficiently induce regulatory B cells in murine systems, translation to human B cells has been limited by inefficiency, lack of scalability, or reliance on poorly defined culture conditions. Consequently, a robust and clinically compatible approach for generating human Bregs has remained elusive. With human peripheral blood B cells as starting materiel, we show that a CD40 targeted IL-21 gain of function fusion protein in combination with TLR9 activation induces a stable regulatory phenotype characterized by IL-10 and granzyme B expression in more than 95% of input B-cells. These induced Bregs display a coordinated transcriptional program distinct from conventional activation, significantly suppress activated human T cell proliferation and modulate inflammatory myeloid responses in vitro. In mice with human T-cell driven xenoGVHD, transfusion of T-cell donor matched Bregs significantly improves survival. These data support the feasibility of Breg manufacturing at scale for use a cellular pharmaceutical.Keywords
Funding Information
- University of Wisconsin in Madison Foundation grant
This publication has 42 references indexed in Scilit:
- Regulatory B cells improve ventricular remodeling after myocardial infarction by modulating monocyte migrationBasic Research in Cardiology, 2021
- Identification and Isolation of Regulatory B Cells in Mouse and Human2019
- Regulatory B Cells: Origin, Phenotype, and FunctionImmunity, 2015
- Changes in regulatory B cells and their relationship with rheumatoid arthritis disease activityClinical and Experimental Medicine, 2014
- B‐type suppression: A role played by “regulatory B cells” or “regulatory plasma cells”?European Journal of Immunology, 2014
- A comparative review of aging and B cell function in mice and humansCurrent Opinion in Immunology, 2013
- B‐regulatory cells in autoimmunity and immune mediated inflammationFEBS Letters, 2013
- Regulation of immunity and autoimmunity by B cellsCurrent Opinion in Immunology, 2010
- Regulatory B cells prevent and reverse allergic airway inflammation via FoxP3-positive T regulatory cells in a murine modelJournal of Allergy and Clinical Immunology, 2010
- Deficiency of regulatory B cells increases allergic airway inflammationInflammation Research, 2005